ClearPath Diagnostics, a physician-owned pathology and cytology laboratory located in Syracuse, says it’s the first laboratory in upstate New York to perform the Cervista HPV HR test. It screens for the presence of high-risk types of the human papillomavirous, which is strongly associated with the development of cervical cancer. FDA-approved Cervista HPV HR is the first new screening test for high-risk HPV in more than a decade, ClearPath says.
The Cervista HPV HR test is used in combination with Pap testing, sharing the same cervical specimen and detects the presence of 14 high-risk HPV types.
Michael A. Jozefczyk, M.D., president of ClearPath Diagnostics, said in a news release that Cervista is the first high-risk HPV assay that includes a quality control check, which will greatly reduce the number of false-positive results.
(Sponsored)
New Sexual Harassment Policy and Training Requirements. Does Your Policy Comply?
New York State requires all employers to provide annual sexual harassment prevention training and a harassment policy to its employees. This requirement applies to all employees, including hourly and salaried,
Don’t Take the Bait: Phishing Scams to Avoid
Americans lost $8.8 billion to phishing and other fraud in 2022, according to the Federal Trade Commission, with financial fraud increasing over 30% from 2021. Every day, thousands of people
ClearPath Diagnostics is also bringing Cervista to the Southern Tier. The company now has a client-service representative in the Binghamton area to serve physicians and the patients they serve.
ClearPath’s pathologist owners are Drs. Josefczyk, Michael Mazur, and Kenneth Strumpf.
